Trial watch: beta-blockers in cancer therapy
Open Access
- 27 November 2023
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 12 (1) , 2284486
Abstract
Compelling evidence supports the hypothesis that stress negatively impacts cancer development and prognosis. Irrespective of its physical, biological or psychological source, stress triggers a physiological response that is mediated by the hypothalamic-pituitary-adrenal axis and the sympathetic adrenal medullary axis. The resulting release of glucocorticoids and catecholamines into the systemic circulation leads to neuroendocrine and metabolic adaptations that can affect immune homeostasis and immunosurveillance, thus impairing the detection and eradication of malignant cells. Moreover, catecholamines directly act on β-adrenoreceptors present on tumor cells, thereby stimulating survival, proliferation, and migration of nascent neoplasms. Numerous preclinical studies have shown that blocking adrenergic receptors slows tumor growth, suggesting potential clinical benefits of using β-blockers in cancer therapy. Much of these positive effects of β-blockade are mediated by improved immunosurveillance. The present trial watch summarizes current knowledge from preclinical and clinical studies investigating the anticancer effects of β-blockers either as standalone agents or in combination with conventional antineoplastic treatments or immunotherapy.Keywords
Funding Information
- reported there is no funding associated
This publication has 198 references indexed in Scilit:
- Targeting of Beta Adrenergic Receptors Results in Therapeutic Efficacy against Models of Hemangioendothelioma and AngiosarcomaPLOS ONE, 2013
- Behavioral stress accelerates prostate cancer development in miceJournal of Clinical Investigation, 2013
- Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signalingBrain, Behavior, and Immunity, 2012
- β2-adrenoceptor blockage induces G1/S phase arrest and apoptosis in pancreatic cancer cells via Ras/Akt/NFκB pathwayMolecular Cancer, 2011
- Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitroRadiation Oncology, 2010
- The β-adrenoceptor antagonist, propranolol, induces human gastric cancer cell apoptosis and cell cycle arrest via inhibiting nuclear factor κB signalingOncology Reports, 2010
- Do Intraoperative Analgesics Influence Breast Cancer Recurrence After Mastectomy? A Retrospective AnalysisAnesthesia & Analgesia, 2010
- Prevention of pancreatic cancer by the beta-blocker propranololAnti-Cancer Drugs, 2009
- Perioperative Use of β-blockers and COX-2 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor MetastasisAnnals of Surgical Oncology, 2008
- The tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone stimulates proliferation of immortalized human pancreatic duct epithelia through β-adrenergic transactivation of EGF receptorsJournal of Cancer Research and Clinical Oncology, 2005